Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
89 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2016, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape. Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively. Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Liver Failure (Hepatic Insufficiency) Overview 8 Therapeutics Development 9 Pipeline Products for Liver Failure (Hepatic Insufficiency) - Overview 9 Pipeline Products for Liver Failure (Hepatic Insufficiency) - Comparative Analysis 10 Liver Failure (Hepatic Insufficiency) - Therapeutics under Development by Companies 11 Liver Failure (Hepatic Insufficiency) - Therapeutics under Investigation by Universities/Institutes 12 Liver Failure (Hepatic Insufficiency) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Liver Failure (Hepatic Insufficiency) - Products under Development by Companies 17 Liver Failure (Hepatic Insufficiency) - Products under Investigation by Universities/Institutes 18 Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development 19 Alfact Innovation 19 BioLineRx Ltd 20 Cell2B Advanced Therapeutics SA 21 Conatus Pharmaceuticals Inc 22 Immune Pharmaceuticals Inc 23 Mina Therapeutics Ltd 24 Mylan NV 25 Ocera Therapeutics Inc 26 PledPharma AB 27 Promethera Biosciences SA 28 Silence Therapeutics Plc 29 TGV-Laboratories 30 Unicyte AG 31 Ventria Bioscience 32 Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 38 Assessment by Molecule Type 40 Drug Profiles 42 ALF-5755 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Antisense RNAi Oligonucleotide for Liver Diseases - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 BL-1220 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Cell Therapy for Liver Failure - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 emricasan - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 F-573 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Hep-114 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 HepaStem - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 ImmuneSafe - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 MTL-CEBPA - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Oligonucleotide for Liver Failure - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 ornithine phenylacetate - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 PP-100 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Recombinant Protein to Inhibit JNK for Liver Failure - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 RNAi Oligonucleotides to Inhibit MAP Kinase 4 for Liver Failure - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 silibinin - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure and Neurodegenerative Diseases - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 VEN-100 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Liver Failure (Hepatic Insufficiency) - Dormant Projects 76 Liver Failure (Hepatic Insufficiency) - Discontinued Products 77 Liver Failure (Hepatic Insufficiency) - Product Development Milestones 78 Featured News & Press Releases 78 Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016 78 Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure 78 Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases 78 Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 79 Oct 05, 2015: Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases 80 Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 81 Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 83 Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 83 Apr 11, 2013: Gene inhibition helps to improve liver regeneration 84 Apr 02, 2013: ALF-5755 phase II completion 85 Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury 85 Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure 86 May 06, 2011: ALF-5755 phase II extends to Germany 87 May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA 87 Appendix 88 Methodology 88 Coverage 88 Secondary Research 88 Primary Research 88 Expert Panel Validation 88 Contact Us 88 Disclaimer 89
List of Tables
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2016 9 Number of Products under Development for Liver Failure (Hepatic Insufficiency) - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Comparative Analysis by Unknown Stage Development, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Investigation by Universities/Institutes, H2 2016 18 Liver Failure (Hepatic Insufficiency) - Pipeline by Alfact Innovation, H2 2016 19 Liver Failure (Hepatic Insufficiency) - Pipeline by BioLineRx Ltd, H2 2016 20 Liver Failure (Hepatic Insufficiency) - Pipeline by Cell2B Advanced Therapeutics SA, H2 2016 21 Liver Failure (Hepatic Insufficiency) - Pipeline by Conatus Pharmaceuticals Inc, H2 2016 22 Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H2 2016 23 Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H2 2016 24 Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H2 2016 25 Liver Failure (Hepatic Insufficiency) - Pipeline by Ocera Therapeutics Inc, H2 2016 26 Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H2 2016 27 Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H2 2016 28 Liver Failure (Hepatic Insufficiency) - Pipeline by Silence Therapeutics Plc, H2 2016 29 Liver Failure (Hepatic Insufficiency) - Pipeline by TGV-Laboratories, H2 2016 30 Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H2 2016 31 Liver Failure (Hepatic Insufficiency) - Pipeline by Ventria Bioscience, H2 2016 32 Assessment by Monotherapy Products, H2 2016 33 Number of Products by Stage and Target, H2 2016 35 Number of Products by Stage and Mechanism of Action, H2 2016 37 Number of Products by Stage and Route of Administration, H2 2016 39 Number of Products by Stage and Molecule Type, H2 2016 41 Liver Failure (Hepatic Insufficiency) - Dormant Projects, H2 2016 76 Liver Failure (Hepatic Insufficiency) - Discontinued Products, H2 2016 77
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
